AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03817853
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide 750 milligrams per square metre (mg/m\^2), administered intravenously (IV) on Day 1 of each 21-day cycle, for six cycles for CHOP treatment or eight cycles for CVP treatment.
Trial: NCT03817853
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxorubicin 50 mg/m\^2 IV, administered on Day 1 of each 21-day cycle, for six cycles.
Trial: NCT01436513
Drug: Premarin reference tablet (fasted)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Premarin reference tablet, single dose, fasted conditions
Trial: NCT01436513
Drug: Premarin new tablet (fasted)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Premarin new tablet, single dose, fasted conditions
Trial: NCT01436513
Drug: Premarin reference tablet (fed)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Premarin reference tablet, single dose, fed conditions
Trial: NCT01436513
Drug: Premarin new tablet (fed)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Premarin new tablet, single dose, fed conditions
Trial: NCT02281344
Drug: MMV390048 20mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supplied as a powder to be prepared as a suspension for oral use
Trial: NCT02840526
Drug: Sopodorm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: midazolam 0,1 mgkg-1 intravenously (anesthesia induction)
Trial: NCT02840526
Drug: Fentanyl WZF
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: fentanyl 1,5 µgkg-1 intravenously (anesthesia induction)
Trial: NCT02840526
Drug: Oxynorm
RxNorm normalized name: Oxynorm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mgml-1 concentration oxycodone solution intravenously
Trial: NCT02840526
Drug: Paracetamol Kabi
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1g paracetamol intravenously every 6 hours
Trial: NCT02840526
Drug: Ketonal
RxNorm normalized name: Ketonal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg ketoprofen intravenously every 12 hours
Trial: NCT00375960
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03068234
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for pirfenidone capsule
Trial: NCT03068234
Drug: Steroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose of glucocorticoids, a basic treatment for patients with systemic sclerosis
Trial: NCT01231529
Drug: GSK1349572
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All subjects will receive a single dose of GSK1349572 50 mg. GSK1349572 is an experimental drug in the integrase inhibitor class being developed for the treatment of HIV infection. GSK1349572 is not approved by the FDA.
Trial: NCT03527316
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules containing mannitol looking identical to the other drugs.
Trial: NCT03091595
Drug: 15 mg E4/3 mg DRSP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg E4/3 mg DRSP combined tablets will be administered orally once daily in a 24/4 day regimen for three consecutive cycles
Trial: NCT03091595
Drug: 20 mcg EE/3 mg DRSP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mcg EE/3 mg DRSP combined tablets will be administered orally once daily in a 24/4 day regimen for three consecutive cycles
Trial: NCT02829008
Drug: Treatment of physician's choice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The clinicians can select any drug or regimen that has been approved in metastatic cancer at present, including monotherapy, combination therapy, target therapy and palliative therapy. Specific agents include taxanes, capecitabine, gemcitabine, vinorelbine, cisplatin,carboplatin, nutrient solutions, and so on. These agents can be administered as monotherapy or in combination.
Trial: NCT00519857
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet p.o, once daily for 3 years
Trial: NCT01766076
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PBMC collected for immune activation assays using flowcytometry
Trial: NCT01445782
Drug: AZD2115
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple dose, oral inhalation (nebuliser solution)
Trial: NCT01445782
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple dose, oral inhalation (nebuliser solution)
Trial: NCT00893880
Drug: 1% gaseous Nitric Oxide blended in Oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% gaseous nitric oxide blended in oxygen applied for 30-60 minutes over 1-2 consecutive days.
Trial: NCT02773147
Drug: Pyridoxine
RxNorm normalized name: PYRIDOXINE
DrugBank: Pyridoxine phosphate (DB02209)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00396682
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 150 - 250 - 350 mg
Trial: NCT01455415
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matching placebo 3 time a day
Trial: NCT00149383
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01294774
Drug: KRP203 - 1.2mg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00762710
Drug: Placebo medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Form: Placebo will be taken orally, in the form of pills.~Dosing: 9 AM, 3 PM, 9 PM~Days 1-2: 0 mg, 0 mg, 1 mg~Days 3-4: 1 mg, 1 mg, 1 mg~Days 5-7: 2 mg, 2 mg, 2 mg~Day 8-10: 2 mg, 2 mg, 6 mg~Day 11-14: 4 mg, 4 mg, 6 mg~Day 15-84: 4 mg, 4 mg, 8 mg
Trial: NCT03308890
Drug: 0.5mg Baraclude(entecavir)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5mg Baraclude (entecavir) QD for 6 months after cessation of TDF.
Trial: NCT03308890
Drug: 0.5mg Baraclude(entecavir)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5mg Baraclude (entecavir) QD for 12 month after cessation of TDF.
Trial: NCT00634036
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matching placebo (inert tablet)
Trial: NCT03514732
Drug: MELATONIN (MELATL07959)
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Pharmaceutical form:Capsule Route of administration: Oral
Trial: NCT03307252
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Film-coated tablet
Trial: NCT01357837
Drug: GRT6005
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 capsules containing a total of 200 µg GRT6005 once a day, in the morning, for a total of 28 days
Trial: NCT00648882
Drug: LEVOTHYROXINE SODIUM TABLETS,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2x300mcg, single dose fasting
Trial: NCT00648882
Drug: SYNTHROID® 300 mcg Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2x300mcg, single dose fasting
Trial: NCT04823065
Drug: hyoscine-n-butylbromide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 X 20 mg Buscopan, intravenous
Trial: NCT04573322
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal Saline, in an equivalent volume by participant body weight, administered via IV bolus every 6 hours for up to 15 days
Trial: NCT00970346
Drug: OligoG CF-5/20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled OligoG CF-5/20 will be given to healthy volunteers with different concentrations to test tolerability of the drug
Trial: NCT03631706
Drug: M7824
RxNorm normalized name: M7824
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received intravenous infusion of M7824 at a dose of 1200 milligrams (mg) once every 2 weeks until confirmed progression of disease, death, unacceptable toxicity, or study withdrawal.
Trial: NCT03858751
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsule before bedtime
Trial: NCT03858751
Drug: LTM1201AZ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LTM1201AZ oral capsule before sleep
Trial: NCT03858751
Drug: LTM1201AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LTM1201AT oral capsule before sleep
Trial: NCT03858751
Drug: LTM1201AD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LTM1201AD oral capsule before sleep
Trial: NCT01195311
Drug: INCB024360
FDA approved: no
EMA approved: no
PMDA approved: no
Description: INCB024360: 25 mg and 100 mg tablets Doses will be escalated in accordance with the dosing schedule.
Trial: NCT00107861
Drug: Ad.hIFN-β (BG00001, IDEC-201)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02712554
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01825473
Drug: Erythromycin
RxNorm normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01825473
Drug: Placebo (D5W)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03067727
Drug: Dinoprostone
RxNorm normalized name: Dinoprostone
DrugBank: Dinoprostone (DB00917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The DVI contains 10 mg Dinoprostone
Trial: NCT03067727
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo product is identical with the active product except that it does not contain Dinoprostone.
Trial: NCT02345980
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00856492
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00856492
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT03692286
Drug: Calcium Hydroxide Intracanal medication
RxNorm normalized name: Calcium Hydroxide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium hydroxide intracanal medication
Trial: NCT03312244
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT02374736
Drug: Privigen (Human normal immunoglobulin G (IgG > 98 % purity))
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Privigen (CSL Behring AG, Bern, Switzerland) 10% liquid human IgG for intravenous administration, 2 g/kg, given as 2 g/kg for 2 days/month for 6 months (maximum dose: 80 g/day).~Privigen will be provided in vials containing 10 g IgG in 100 mL.
Trial: NCT04332094
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 500 mg / day v.o. for 3 days
Trial: NCT04200651
Drug: Prednisolone Acetate 1% Oph Susp
RxNorm normalized name: PREDNISOLONE ACETATE 1% OPH SUSP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisolone acetate 1% eye drops are used 2-4 times daily for 30 days as the current standard of care for treating inflammation and eye pain after cataract surgery. Prednisolone, like dexamethasone, is a steroid. This arm will also receive the standard of care topical ofloxacin eye drop antibiotic regimen.
Trial: NCT01769573
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo to be used will be Minimal Essential Media (MEM, HyClone) containing 0.1% Human Serum Albumin. Placebo will be supplied in 2 ml borosilicate glass vials sealed with butyl stoppers containing 0.5 ml.
Trial: NCT01950468
Drug: NAV5001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single intravenous dose of 8.0 ± 1.0 mCi
Trial: NCT03441412
Drug: Epinephrine
RxNorm normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2 x 90 mg of ticagrelor will be administered orally to the subjects. Two hours after administration, the registrations and blood sampling are repeated after which an infusion of epinephrine diluted in glucose solution (5%) is started at a weight-adjusted rate of 0.01, 0.05, 0.10 and 0.15 μg kg-1 min-1. Each infusion will be maintained for 15 minutes.~After the measurement at the highest dose of epinephrine, 5 mg metoprolol (Abcur, Haelsingborg , Sweden) will be given intravenously to the study subject and thereafter registrations and blood sampling will be repeated.
Trial: NCT03292666
Drug: Oral Anticoagulant
RxNorm normalized name: CPDA-1 Anticoagulant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral anticoagulants used to treat or prevent venous thromboembolism
Trial: NCT02563054
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants will receive oral capecitabine, 1000 mg/m\^2 twice daily on Days 1 to 14 of each 3-week cycle, for a total of 6 cycles in combination with cisplatin or upto disease progression.
Trial: NCT04527133
Drug: Aprotinin
RxNorm normalized name: Aprotinin
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous or inhalation
Trial: NCT03144661
Drug: INCB062079
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In Part 1, initial cohort dose of INCB062079 at the protocol-defined starting dose, with subsequent dose escalations based on protocol-specific criteria. The recommended dose(s) from Part 1 will be taken forward into Part 2 cohorts.
Trial: NCT02153177
Drug: Ibuprofen, Hydrocodone/Acetaminophen, Omeprazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In addition to pain medication after the procedure patients will receive Ibuprofen and Omeprazole. Omeprazole is given to minimize the gastrointestinal side effects of Ibuprofen.
Trial: NCT02513160
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, taken in the morning and evening each day, was provided in matching BAI and MDI devices.~The placebo devices were identical to the devices used to deliver active drug.
Trial: NCT02729025
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered subcutaneously once a month using an autoinjector/pen.
Trial: NCT00295581
Drug: PpPfs25/ISA51 & ScPvs25/ISA51
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00533481
Drug: MK0557
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01415518
Drug: theophylline SR
RxNorm normalized name: Theophylline SR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: theophylline SR (0.1g/tablet, 1 tablet p.o. twice daily)
Trial: NCT00240448
Drug: valsartan 160 mg/hydrochlorothiazide 25 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00240448
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02416063
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug:Caudal bupivacaine 0.25% 1ml/kg~Intravenous: Normal saline 10 ml~sevoflurane Induction and maintenance of anesthesia
Trial: NCT00632268
Drug: RAD001; Cisplatin; 5-FU; Leucovorin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RAD001: oral 10mg/day on Day 1,8,15 Cisplatin:infusion 35mg/m2/day on Day 1,8 5-FU:infusion 2000mg/m2/day on Day 1,8,15
Trial: NCT00663936
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo once daily
Trial: NCT02253511
Drug: Cidan capsule
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03334240
Drug: CLS003
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CLS003
Trial: NCT03334240
Drug: Vehicle
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle
Trial: NCT00324818
Drug: metronidazole and azithromycin
RxNorm normalized name: metronidazole and diloxanide
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03456102
Drug: Pravastatin
RxNorm normalized name: Pravastatin
DrugBank: Pravastatin (DB00175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Phase IIB clinical trial: A two-week safety/PK study to determine pravastatin exposures over 24 hours when given together with first-line treatment (HRZE) and ensure the combination is safe and well-tolerated.~A two-week safety/PK study to determine pravastatin exposures over 24 hours when given together with first-line treatment (HRZE) and ensure the combination is safe and well-tolerated.
Trial: NCT02453932
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo identified to Tianzhi granule (5g, 3 times per day) and placebo identified to donepezil ,1 pills per day for 24 weeks
Trial: NCT01037842
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo three times a day added to metformin 500 mg three times a day for 16 weeks
Trial: NCT01697072
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine is an oral fluoropyrimidine.
Trial: NCT00513695
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00513695
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given PO
Trial: NCT03861390
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediately following exit from the wood smoke chamber, subjects will receive a matching placebo to the 60 mg of prednisone per randomization schema
Trial: NCT01907490
Drug: Ha44 Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eligible subjects will be treated at the study site on Day 0 with a single application of the maximum feasible amount of Ha44 Gel, to ensure saturation of the scalp and hair.
Trial: NCT00933023
Drug: hydrocortisone
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 1%hydrocortisone topical once daily for 8 weeks
Trial: NCT04380935
Drug: Standard of care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: According to national or hospital guidelines COVID-19 Management Protocol
Trial: NCT01173523
Drug: STA-9090
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00151879
Drug: SPM 927
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03390608
Drug: Endocrine therapy
RxNorm normalized name: ENDOCRINE THERAPY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endocrine treatment versus no endocrine therapy (in women with hormone receptor positive1 disease).
Trial: NCT03390608
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy versus no chemotherapy.
Trial: NCT02029118
Drug: Herbal plaster ( styrax, borneol, frankincense, santalum,trichosanthes kirilowii Maxim, allium macrostemon Bunge, leech)
RxNorm normalized name: Trichosanthes kirilowii fruit rind
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Application containing herbal medicine that mainly include styrax, borneol, frankincense, santalum,trichosanthes kirilowii Maxim, allium macrostemon Bunge, leech and other herbal medicine.
Trial: NCT00920868
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 850 mg/m2 PO BID on days 1-14
Trial: NCT00469430
Drug: cefotaxim and metronidazol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iv administration for at least 24 h
Trial: NCT00707239
Drug: tigecycline
RxNorm normalized name: Tigecycline
DrugBank: Tigecycline (DB00560)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: An initial intravenous (IV) loading dose of 150 mg of tigecycline, followed by 75 mg of IV tigecycline approximately every 12 hours (q12h), for up to 14 consecutive days. Ceftazidime 2 g IV approximately every 8 hours, an aminoglycoside (tobramycin 7mg/kg daily or amikacin 20 mg/kg daily) and vancomycin placebo given at the start of therapy (unless it is known at baseline that the subject does not have Pseudomonas aeruginosa or methicillin-resistant Staphylococcus aureus \[MRSA\]).
Trial: NCT00707239
Drug: tigecycline
RxNorm normalized name: Tigecycline
DrugBank: Tigecycline (DB00560)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: An initial intravenous (IV) loading dose of 200 mg of tigecycline, followed by 100 mg of IV tigecycline approximately every 12 hours (q12h), for up to 14 consecutive days. Ceftazidime 2 g IV approximately every 8 hours, an aminoglycoside (tobramycin 7mg/kg daily or amikacin 20 mg/kg daily) and vancomycin placebo given at the start of therapy (unless it is known at baseline that the subject does not have Pseudomonas aeruginosa or methicillin-resistant Staphylococcus aureus \[MRSA\]).
Trial: NCT02129231
Drug: Ezetimibe/simvastatin
RxNorm normalized name: EZETIMIBE/SIMVASTATIN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: We ensured the patient took the drug at night before meals
Trial: NCT02129231
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: We ensured the patient took the drug at night before meals
Trial: NCT00063934
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00843050
Drug: P276-00
FDA approved: no
EMA approved: no
PMDA approved: no
Description: P276-00: All patients will receive P276-00 185 mg/m2/day as intravenous infusion over 30 minutes in 200 ml of 5% dextrose from day 1 to day 5 in each 21 days cycle for minimum 6 and maximum 12 cycles or until there is progression of disease or unacceptable toxicity
Trial: NCT02234141
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet administered orally once daily
Trial: NCT04285853
Drug: Placebo oral tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets (both trial and rescue) will be matched to size, shape, color, and texture of oxycodone tablets.